Repurposed Drug Evaluation for Biological Aging, Pain, and Inflammation Reduction in Osteoarthritis

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524885-12-00

Enrollment

175

Registered

2026-05-26

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

Change in epigenetic and biological age acceleration before and after medication use.

Detailed description

Change in inflammatory proteins and cytokines in the circulation before and after medication use., Change in pain severity and the knee osteoarthritis biomarkers in the blood and urine before and after medication use., Safety of the drug combinations assessed by the proportion of treatment emergent adverse events and grade 3/4 laboratory abnormalities.

Interventions

DRUGTivicay 50 mg film-coated tablets

DRUGMETFORMINE HCL SANDOZ 500 MG

DRUGfilmomhulde tabletten

DRUGColchicine CF 0

DRUG5 mg

DRUGtabletten

DRUGOlumiant 2 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in epigenetic and biological age acceleration before and after medication use.	—

Secondary

Measure	Time frame
Change in inflammatory proteins and cytokines in the circulation before and after medication use., Change in pain severity and the knee osteoarthritis biomarkers in the blood and urine before and after medication use., Safety of the drug combinations assessed by the proportion of treatment emergent adverse events and grade 3/4 laboratory abnormalities.	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 27, 2026